feed,title,long_url,short_url
ðŸ’°Barrons,Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment,https://barrons.com/articles/replimune-repl-stock-price-news-739b7fe8?mod=RTA,
